contact@asploro.com
Diabetes Research: Open Access

DROA

Diabetes Research: Open Access

About this Journal

Diabetes Research: Open Access is an Open Access Journal which releases Scholarly Articles featuring the content about Diabetes and Endocrinology.

The extent of the journal incorporates endocrine organs, hormonal discharges, hormonal receptors and the hormone controlled metabolic pathways. It also includes the clinical investigation of disorders related to Diabetes.

The articles including diabetes featured symptoms, causes, pathophysiology, conclusion,…

Submit manuscript as an e-mail attachment to the Editorial Office at diabresearch@clinicalsci.com or through online at Submit Manuscript

Associations and Collaborations

Diabetes Research: Open Access is associated with Japanese Low Carbohydrate Diet Promotion Association – In Japan, Dr. Koji EBE, MD, PhD and colleagues have established Japanese LCD Promotion Association (JLCDPA) and developed their activities as follows:

i) Beneficial information of LCD on the website concerning 77 affiliated hospitals and clinics so far.

ii) Seminars and workshops have continued for years, including 11 seminars and 19 cooking workshops in large cities.

Why Publish With Us

  • All the published articles are open access which means it’s free to access from anywhere in the world.
  • Each case published in this journal can improve health outcomes.
  • We offer fast publication while providing rigorous peer review to maintain the integrity of information.
  • Each article will be published under a Creative Commons license and authors are the copyright holder.
  • We are committed to the highest standards of peer review.
  • We’re proud of the impact and influence this journal have – from citations to social media shares.
  • We’re committed to promoting your work as widely as we can and providing as much visibility and exposure for your article as possible.

Tweets

Latest Papers

Abstract

For the current critical situation of COVID-19 worldwide, several recommended hints for improved lifestyle and health were described from integrative medicine (IM) point of view. It includes some categories as follows. i) Exercise: Hippocrates said that walking is the best medicine. Walking fast, climbing stairs, and squats are effective. ii) Sleep and rhythmic lifestyle: Keep sleep and wake up time regularly, avoid looking at display or VDT work before sleep, and have bright light when waking up, especially sunlight. iii) Mental care: The US CDC presents the stressful influences, such as fear and worry about health, worsening of chronic health problems, and increased use of alcohol. Some recommendations of controlling heart and minds include keeping the natural feeling of being as it is, and mindfulness related to the oriental Zen concept. iv) Nutrition: IM and anti-inflammatory diet were proposed by Dr. Andrew Weil at Arizona University. The diet is based on two diets—the Mediterranean diet and the Okinawan diet. v) IM: Several applicable tips for IM show chiropractic, aromatherapy, supplements, medical herbs, Chinese medicine, Ayurveda, acupuncture, and others.

Author(s): Fennoun H, Haraj NE, El Aziz S, Bensbaa S, Chadli A*
Abstract

Introduction: Hyperuricemia is common Type 2 diabetes at very high cardiovascular risk.

Objective: Evaluate the relationship between hyperuricemia and diabetes type 2, and determine its predictive factors in this population.

Patients and Methods: Retrospective study cross including 190 patients with diabetes type 2 hospitalized Service of Endocrinology of CHU Ibn Rushd Casablanca from January 2015 to December 2017. Hyperuricemia was defined as a serum uric acid concentration> 70 mg/L (men) and> 60 mg/L (women). The variables studied were the anthropometric measurements), cardiovascular factors (tobacco, hypertension, dyslipidemia), and degenerative complications (retinopathy, neuropathy, kidney failure, ischemic heart disease). The analyzes were performed by SPSS software.

Results: Hyperuricemia was found in 26.5% of patients with a female predominance (76%), an average age of 55.9 years, and an average age of 12.4ans diabetes. The glycemic control was found in 84.6% of cases with mean glycated hemoglobin 8.6%.

Factors associated al hyperuricemia were the blood pressure in 86% (p <0.05), dyslipidemia in 76.3% of cases (p <0.001) with hypertriglyceridemia in 48.3% of cases (p <0.02), and a hypoHDLémie 28% (p <0.001). The age, obesity, smoking, and glycemic control were associated significantly n al hyperuricemia.

The research of degenerative complications of hyperuricemia has objectified renal impairment (GFR between 15 and 60ml / min) chez47% (p <0.001), it was kind of moderate in 35.8% (p <0.01) and severe in 5.1% (p <0.02), ischemic heart disease was found in 34% of cases (p <0.01).

Conclusion: In our study, hyperuricemia in type 2 diabetes is common in female patients, especially with hypertension, dyslipidemia, and renal failure. Other factors such as age, obesity, smoking is not associated with hyperuricemia in type 2 diabetics.

Take an animal, birds, and fish chopped bile juice and mixed it with 50% Bile juice and 50% ethyl alcohol/rectified spirit and shake well in a bottle and keep it for 12 hours. After 12 hours all particles will sit at the bottom and we can use 1 drop upper site extract by oral administration. Repeated dose along with other drugs, it can develop immunity because I use it and found fruitful result in cough cold and digestion. I hope that it will kill all kinds of Virus and people will recover from this deadly virus. It is my humble request to the WHO and every Government agency to experiment on this topic and save the world by COVID-19.

We can use 50% ethyl alcohol and 50% bile juice and mix and give to critical patients for the experiment. I have attached the report from the Central Drug Research Institute Lucknow about the analysis of substance that no harmful substance is present in it (Fig-1 and Fig-2). Although the taste is bitter, it is lifesaving in critical circumstances and vaccines can be made using this composition.

How Can We Develop Immunity against COVID-19 and Defeat It
Abstract

The case was a 55-year-old female patient with depression for 5 years and type 2 diabetes mellitus (T2DM) for 3 years. She has received anti-depressant and anti-hyperglycemic agents (OHAs). Approximately 1 year ago, her diabetic control became exacerbated without specific triggers. She was started to given Ipragliflozin L-Proline as Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor. After that, her glucose variability and depression had been improved. According to the previous reports, SGLT-2 inhibitors seem to have anti-depression efficacy for diabetes. The case has been followed up in detail, and this report is expected to be a useful reference for diabetes care.

Effective SGLT2 Inhibitor for Patient with Type 2 Diabetes Mellitus (T2DM) and Depression
Author(s): Sumida Y*, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Eguchi Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD)
Abstract

A fourth of the adult population is now suffering from nonalcoholic fatty liver disease (NAFLD) worldwide. Nonalcoholic steatohepatitis (NASH), a severe form of NAFLD, can lead to liver-related mortality. NAFLD/NASH is closely associated with type 2 diabetes. Although pioglitazone is now recommended as the 1st line therapy for NASH with type 2 diabetes, pioglitazone has several safety concerns such as body weight gain, heart failure, fluid retention, and bone fracture in women. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have a variety of functions such as glycemic control, bodyweight reduction, and decreased body pressure. Accumulating evidence has shown that this agent has also cardioprotective and renoprotective effects in patients with or without type 2 diabetes. Recent studies that SGLT2 inhibitor can also reduce in transaminase activities or hepatic fat content in NAFLD. NAFLD patients with type 2 diabetes can be indicated for SGLT2 inhibitor, because they are obese, have insulin resistance, and at high risk of cardiovascular events. The phase 3 study of dapagliflozin for NAFLD (DEAN study) is now ongoing. It remains unknown whether this agent can ameliorate hepatic fibrosis in NASH, leading to improved over-all or liver-related survival. Since the leading cause of NAFLD mortality is cardiovascular events, SGLT2 inhibitors will become the 1st line treatment for NAFLD/NASH.

Hepatoprotective Effect of SGLT2 Inhibitor on Nonalcoholic Fatty Liver Disease
Hepatoprotective Effect of SGLT2 Inhibitor on Nonalcoholic Fatty Liver Disease